Takeda’s Entyvio outperforms AbbVie’s Humira in moderate-to-severe ulcerative colitis

pharmafile | September 27, 2019 | News story | Medical Communications, Research and Development AbbVie, Entyvio, Humira, Takeda, pharma, ulcerative colitis 

Takeda has released strong new data for Entyvio (vedolizumab), showing that the gut-selective biologic outperformed AbbVie’s blockbuster anti-tumour necrosis factor-alpha (TNFα) biologic Humira (adalimumab) in the treatment of moderately to severely active ulcerative colitis (UC).

Data showed that 34.2% of anti-TNFα-naïve patients treated with Entyvio saw clinical remission after 52 weeks of treatment compared to 24.3% with Humira, meeting the trial’s primary endpoint, while these rates stood at 20.3% in anti-TNFα-experienced patients compared to 16%.

Furthermore, 26.6% of Entyvio patients reached clinical remission after just 14 weeks, while only 21.2% of Humira patients could say the same.

The data also showed that a greater proportion of Entyvio patient saw an improvement in their quality of life, with 52% reporting a ≥16-point improvement in total Inflammatory Bowel Disease Questionnaire (IBDQ) scores from baseline after 52 weeks, compared to 42.2% with Humira.

“In a chronic, debilitating condition like ulcerative colitis, it is essential that patients gain relief from the many different aspects of the disease,” remarked Dr Bruce E Sands, primary investigator of the VARSITY study and Chief of the Dr Henry D Janowitz Division of Gastroenterology at The Mount Sinai Hospital and the Icahn School of Medicine in New York. “The VARSITY results provide physicians with valuable insights to support their treatment decisions when initiating biologic therapy in patients with ulcerative colitis.”

Dr Jeff Bornstein, Executive Medical Director at Takeda, added: “The VARSITY study, a first-of-its-kind comparison of two biologics in ulcerative colitis, shows the benefits vedolizumab treatment provides to patients versus adalimumab across efficacy outcomes, in addition to improvements in overall quality of life. These data further support the use of vedolizumab as a first-line biologic therapy in ulcerative colitis.”

Matt Fellows

Related Content

AstraZeneca and MSD’s Lynparza receives NICE positive recommendation as a cancer maintenance treatment

UK-based pharmaceutical company AstraZeneca has announced that the National Institute for Health and Care Excellence …

FDA grants Priority Review for Takeda’s cTTP treatment

Japanese biopharmaceutical company Takeda has announced that the US Food and Drug Administration (FDA) has …


Takeda collaboration to optimise biopharmaceutical manufacturing announced

A 36-month joint project between Takeda’s manufacturing site in Vienna, the Research Center Pharmaceutical Engineering …

Latest content